TORONTO, July 17, 2026 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (TSX Venture: ARCH and OTCQB: ACHFF) today announced that it has engaged a U.S.-based laboratory specializing in bioengineering to accelerate the Company’s pre-IND IL-32 chronic kidney disease (“…
The Companys ongoing engagement of RCSI remains subject to approval by the TSXV. About Red Cloud Securities Inc. Red Cloud Securities Inc. is headquartered in Toronto, Ontario. RCSI is registered a…